Ngam Advisors L.P. raised its position in Allergan PLC. (NYSE:AGN) by 4.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,063 shares of the company’s stock after buying an additional 2,851 shares during the period. Ngam Advisors L.P.’s holdings in Allergan PLC. were worth $17,695,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the company. Segall Bryant & Hamill LLC raised its position in shares of Allergan PLC. by 3.2% in the first quarter. Segall Bryant & Hamill LLC now owns 111,513 shares of the company’s stock worth $26,643,000 after buying an additional 3,410 shares during the period. South Dakota Investment Council raised its position in shares of Allergan PLC. by 0.6% in the first quarter. South Dakota Investment Council now owns 201,509 shares of the company’s stock worth $48,145,000 after buying an additional 1,240 shares during the period. Golub Group LLC raised its position in shares of Allergan PLC. by 7.3% in the first quarter. Golub Group LLC now owns 214,207 shares of the company’s stock worth $51,178,000 after buying an additional 14,623 shares during the period. Capital Planning Advisors LLC raised its position in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after buying an additional 1,625 shares during the period. Finally, Cornerstone Wealth Management LLC acquired a new position in shares of Allergan PLC. during the first quarter worth about $285,000. 84.53% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC. (AGN) opened at 249.07 on Friday. The stock’s 50 day moving average price is $239.66 and its 200-day moving average price is $234.93. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $261.27. The firm has a market cap of $83.65 billion, a P/E ratio of 7.76 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.32 by $0.03. Allergan PLC. had a net margin of 82.42% and a return on equity of 7.29%. The business had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. During the same quarter last year, the business posted $3.04 earnings per share. Allergan PLC.’s revenue for the quarter was up 5.1% compared to the same quarter last year. Equities research analysts anticipate that Allergan PLC. will post $16.08 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (AGN) Stake Raised by Ngam Advisors L.P.” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/07/21/allergan-plc-agn-stake-raised-by-ngam-advisors-l-p.html.
A number of brokerages recently issued reports on AGN. Credit Suisse Group reissued an “outperform” rating and issued a $286.00 price objective (up from $274.00) on shares of Allergan PLC. in a report on Thursday. Deutsche Bank AG reissued a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a report on Monday. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a report on Sunday, July 16th. Piper Jaffray Companies reissued a “hold” rating and issued a $231.00 price objective on shares of Allergan PLC. in a report on Friday, July 14th. Finally, Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a report on Tuesday, July 11th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $273.78.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.36% of the stock is currently owned by company insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.